Guidance Breakdown: FDA Highlights Postapproval Requirements and Resources for ANDAs
The FDA is pulling postapproval reminders out of ANDA approval letters. We break down the new reference guidance that replaces them and the obligations every approved generic has to keep on its radar.
This guidance breakdown is available in full to paid subscribers. Only paid subscribers get regular full access to our guidance breakdowns and other analyses. If you’re not already a paid subscriber, you can upgrade here.
We’re catching up with the FDA’s recent guidances, starting with a new final one from CDER’s Office of Generic Drugs: Certain Postapproval Requirements and Resources for ANDAs.
The story behind it is short: The FDA has been trimming the standardized postapproval reminders it used to print in ANDA approval letters and consolidating them into this reference document instead.
If your team has treated the approval letter as its postapproval checklist, that habit is now on borrowed time! The obligations themselves have not changed. What’s changing is that the FDA is no longer going to spell them all out for you at the moment of approval.
One caveat the guidance makes about itself is worth stating up front: this document does not cover every postapproval requirement that may apply to an ANDA, nor does it list every relevant CDER guidance. It covers “certain” requirements and points to “related” resources. Treat it as a starting map, not the whole territory. Everything below applies to ANDAs that have received final approval.
Here’s what’s on the map.
Changes and supplements to an approved ANDA
Some manufacturing changes to an approved ANDA require an approved supplement before you can make the change and distribute product made with it. That comes from section 506A of the FD&C Act, with the implementing regulations at 21 CFR 314.70 and 314.97.
How much reporting a change triggers depends on its potential to affect the product, and the long-standing reference is Changes to an Approved NDA or ANDA (April 2004, Rev. 1). The point worth holding onto here is that if a change is the kind that needs prior approval, you cannot make it first and report it later.
The tentative-approval trap after a lost patent suit
Read this section closely if you have launched, or plan to launch, on a paragraph IV certification while patent litigation is still live.
Let’s run through it:
The setup first:
An ANDA has to carry a patent certification for each relevant listed patent for the RLD. A paragraph IV certification asserts the patent is invalid, unenforceable, or will not be infringed.
Filing it triggers notice to the NDA holder and patent owner, and if they sue within 45 days, FDA’s approval of the ANDA is generally stayed for 30 months.
FDA can still grant final approval at the end of that 30-month stay with the lawsuit pending, as long as the ANDA has no paragraph III certifications, isn’t blocked by unexpired exclusivity, and meets every other approval requirement.
Now the trap!
After that approval, the patent owner can still win. If a federal district court rules that the patent is infringed and orders that the ANDA approval is not effective until the patent expires, the FDA has to decide whether to convert your approval back to tentative approval, and on what timing.
To let FDA do that cleanly, the ANDA applicant is required to submit the relevant court documents under 21 CFR 314.107(e) within 14 days of the court’s entry of the order, the date of appeal, or the expiration of the time to appeal.
The FDA will weigh the judgment along with any showing that it has been stayed or that a stay motion is pending.
The exposure is real here. A product you are already selling can have its approval pulled back to tentative, and the 14-day window to get documents in is short.
The reference is MAPP 5220.2.
Postmarketing reporting: safety, combination products, and shortages
Postmarketing reporting applies whether or not you are actively marketing the product. The core regulations sit at 21 CFR 314.80, 314.81, and 314.98, and they include keeping the FDA informed of the product’s marketing status. FDARA added section 506I in 2017, which layers on additional marketing-status reporting in certain circumstances, with the companion guidance Marketing Status Notifications Under Section 506I (August 2020).
On safety surveillance, every approved ANDA holder has to maintain written procedures for collecting, evaluating, and reporting postmarketing adverse drug experiences, and has to review adverse experience information from any source, foreign or domestic, including commercial use, postmarketing studies, and the published and unpublished literature.
Periodic safety reports are due quarterly for the first three years after the U.S. approval date and annually after that. The annual report has to summarize significant new information from the prior year that could affect the product’s safety, effectiveness, or labeling, plus what you have done or plan to do about it. The current standards reference is the final E2D(R1) guidance (March 2026, Revision 1).
If your product meets the definition of a combination product under 21 CFR 3.2(e), the combination-product postmarketing safety reporting rule applies on top of the standard requirements. See Postmarketing Safety Reporting for Combination Products (July 2019).
Shortage notifications are their own obligation, and timing matters to the FDA here.
Under section 506C, you have to notify the FDA of a permanent discontinuance or an interruption in manufacturing that is likely to cause a meaningful supply disruption, and that duty covers both finished products and the API for those products.
Four triggers in total:
Discontinuance of a finished product
An interruption in a finished product likely to meaningfully disrupt supply,
Discontinuance of API
An interruption in API likely to meaningfully disrupt API supply
The notification has to state the reasons. The reference is the draft guidance Notifying FDA of a Discontinuance or Interruption in Manufacturing of Finished Products or Active Pharmaceutical Ingredients Under Section 506C (February 2024, Rev. 1).
Promotional materials
When you put out promotional labeling or advertising for a prescription generic, you have to submit a specimen to the FDA at the time of first dissemination or first publication, on a Form FDA 2253, with the product’s current professional labeling attached.
Separately, you can ask the Office of Prescription Drug Promotion for advisory comments on proposed launch materials before they run. That review is voluntary, submitted in eCTD format with the draft or mock-up materials, annotated references, and the applicable labeling. It is a useful check when a campaign is high-stakes, but using it is your call.
Annual facility fees and self-identification
If you own a facility that makes generic drug products or APIs, or a site that supports their manufacture or approval, GDUFA requires you to self-identify with the FDA electronically and update that information every year.
Self-identification feeds two things: the list of facilities that owe user fees, and the FDA’s visibility into the generic supply chain. Most facilities that self-identify owe an annual facility fee. GDUFA III runs from October 1, 2022, through September 30, 2027. For the mechanics, see Self-Identification of Generic Drug Facilities, Sites, and Organizations (September 2016) and the FDA’s GDUFA pages, which carry the current-year fee amounts.
Keeping labeling current
Content of labeling goes to the FDA electronically, currently in structured product labeling (SPL) format, under 21 CFR 314.94(d).
The part that gets under-resourced is the ongoing duty.
Your obligation to keep labeling accurate does not end at approval. When new information makes your labeling inaccurate, false, or misleading, you have to act to correct it, and you are expected to watch the RLD’s labeling for changes and update yours to match. In practice that means routinely checking Drugs@FDA and the Orange Book rather than waiting to be told. The how-to is Revising ANDA Labeling Following Revision of the RLD Labeling (January 2024).
REMS obligations for generics
If the FDA requires a REMS for the listed drug your ANDA references, your ANDA needs a REMS too!
A few specifics particular to generics are worth knowing:
Your ANDA’s REMS has to carry the same Medication Guide or patient package insert, and the same packaging or disposal requirement, as the listed drug.
If the listed drug’s REMS includes Elements to Assure Safe Use (ETASU), your ANDA can either join a single, shared-system REMS with the listed drug or use a different but comparable aspect of those elements, though the FDA can require the shared system if it concludes no comparable alternative would satisfy the statute.
An ANDA REMS does not include a communication plan, and ANDAs are not subject to the standard statutory timetable requirement for REMS assessments, although the FDA can still require REMS assessments when needed and include the schedule in the ANDA approval letter.
Two exclusivity clocks, two different notification rules
Sections H and I of the guidance both deal with telling the FDA when you start selling, and the fastest way to get burned is to assume the two work the same way/ They do not!
Competitive generic therapy (CGT) exclusivity is the first.
If the FDA has designated a drug as a CGT, and there were no unexpired patents or exclusivities listed for the RLD when you submitted your original ANDA, the first approved applicant can earn 180 days of exclusivity by commercially marketing within 75 calendar days of approval.
The wrinkle is on the FDA’s side: the Agency generally will not know you have started marketing unless you tell it. So, the FDA will assume you have not started, and that no CGT exclusivity is blocking the next applicant, unless you send written confirmation that you have begun. And it will treat the exclusivity as forfeited if you do not confirm within that 75-day window.
The statute and regulations do not require a first approved applicant to send this notice, but the assume-forfeiture default makes sending it the only safe move.
The FDA asks for a general correspondence to the ANDA, with a duplicate to the Office of Generic Drugs’ Patent and Exclusivity Team at CDER-OGDPET@fda.hhs.gov.
The 180-day exclusivity tied to a paragraph IV certification works differently.
It goes to the first applicant, meaning the first to file a substantially complete ANDA with a paragraph IV certification to a listed patent.
If several file on the same first day, they share that status. This exclusivity is triggered by the first commercial marketing by any first applicant, and the FDA reads that to include a first applicant marketing an authorized generic, even before that applicant’s own ANDA is approved.
Here, the notification is mandatory: a first applicant has to notify the FDA within 30 days of first commercial marketing. Miss that window and the FDA will deem your first commercial marketing date to be the date your ANDA was approved, which can move your exclusivity clock out from under you!
See Competitive Generic Therapies (October 2022, Rev. 1) and the draft 180-Day Exclusivity: Questions and Answers (January 2017).
The short version: CGT is a 75-day deadline to start selling, with notice that is technically optional but practically required. Paragraph IV is a 30-day deadline to report selling once you have started, with notice that is mandatory and a costly default if you miss it.
Compendial standards
If your drug’s name is recognized in the USP-NF, it generally has to meet the compendial standard for strength, quality, and purity unless any difference is stated plainly on the label.
One practical wrinkle the guidance flags here is that the FDA usually cannot share the application-specific information in your filings with third parties, and that includes USP. So if a monograph needs to change for your product to keep complying, you may need to work with USP directly to revise it.
A few checklist items to consider
If you hold approved ANDAs, here is where this guidance should prompt some internal work. A few of our suggestions:
Build or refresh an internal postapproval obligations register, owned by a named person. With the FDA pulling reminders out of approval letters, the tracking burden shifts entirely to you. Map each obligation in this guidance to a responsible function, a trigger, and a deadline, and stop relying on the letter to surface them.
For any at-risk or paragraph IV launch, pre-stage the 314.107(e) document package and assign the 14-day clock to a specific owner before you go to market. If you lose the patent suit, you do not want to be assembling court documents from scratch against a two-week deadline while also managing the commercial fallout of a possible conversion back to tentative approval.